Anthem Blue Cross and Blue Shield | Medicare AdvantageAMH Health, LLC | Medicare AdvantageMarch 19, 2025
Medicare Part B preapproval expands with new drug additions
Effective for dates of service on and after July 1, 2025, the specialty Medicare Part B drugs listed below will be included in our preapproval review process.
Federal and state law, as well as state contract language and CMS guidelines, including definitions and specific contract provisions/exclusions, take precedence over these preapproval rules and must be considered first when determining coverage. Please follow the new requirements to ensure your claims are accepted.
HCPCS or CPT® codes | Medicare Part B drugs |
C9399, J9999 | Aucatzyl (obecabtagene autoleucel) |
Q5139 | Bkemv (eculizumab-aeeb) |
J3590 | Epysqli (eculizumab-aagh) |
C9399, J3590 | Hympavzi (marstacimab-hncq) |
J3590 | Imuldosa (ustekinumab-srlf) |
J3590 | Otulfi (ustekinumab-aauz) |
Q9997 | Pyzchiva IV (ustekinumab-ttwe) |
Q9998 | Selarsdi (ustekinumab-aekn) |
C9399, J9999 | Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) |
C9399, J9999 | Vyloy (zolbetuximab-clzb) |
Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Maine, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.
MULTI-BCBS-CR-077630-25-CPN77426
To view this article online:
Or scan this QR code with your phone